topotecan

FDA Drug Profile — HYCAMTIN

topotecan is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including HYCAMTIN. Available dosage form: capsule.

Drug details

Generic Name
topotecan
Brand Names
HYCAMTIN
Application Number
NDA020981
Sponsor
Sandoz Inc
NDC Codes
2
Dosage Forms
CAPSULE
Routes
ORAL
Active Ingredients
TOPOTECAN HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Topotecan Injection is indicated for the treatment of: small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies ( 14 ) ] . Topotecan Injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is a topoisomerase inhibitor indicated for: small cell lung cancer sensitive disease after failure of first-line chemotherapy. ( 1 ) combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.